Genmab

Genmab is an international biotechnology company that develops antibody therapeutics intended to transform cancer treatment and address other serious diseases. Founded in 1999, the company operates from a headquarters in Denmark, with additional offices in the Netherlands, the United States, Japan and the United Kingdom, giving it a presence across five countries and more than two decades of continuous operation.

The company's work spans antibody discovery, antibody engineering and the development of proprietary technology platforms, through clinical development and commercialization. Its principal focus is oncology. Genmab has multiple approved antibody therapeutics marketed globally for cancer and other serious diseases, and numerous investigational medicines in clinical development based on its proprietary antibody technology platforms.

Genmab works in the biotechnology, pharmaceuticals, oncology, healthcare and antibody therapeutics sectors. The organization describes itself as global and international, with a stated commitment to pushing the boundaries of antibody science to address unmet medical needs and to improving patients' lives through breakthrough medicines.